Novartis is buying the rights to potential cardiovascular medicines from a Chinese biotech in a deal worth up to $5.2bn, as big pharmaceutical companies become increasingly reliant on Chinese innovation to replenish their drug pipelines.
随着大型制药公司日益依赖manbetx3.0 创新来补充其在研药物管线，诺华(Novartis)正以最高达52亿美元的交易，从一家manbetx3.0 生物科技公司手中收购潜在心血管药物的相关权益。
您已阅读10%（319字），剩余90%（2774字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。